Lansoprazole

Chemical formula: C₁₆H₁₄F₃N₃O₂S  Molecular mass: 369.361 g/mol  PubChem compound: 3883

Therapeutic indications

Lansoprazole is indicated for:

Duodenal ulcer

Population group: only adults (18 years old or older)

Treatment of duodenal ulcer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Gastric ulcer

Population group: only adults (18 years old or older)

Treatment of gastric ulcer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Zollinger-Ellison syndrome

Population group: only adults (18 years old or older)

Zollinger-Ellison syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Eradication of Helicobacter pylori

Population group: only adults (18 years old or older)

Helicobacter pylori gastrointestinal tract infection

For this indication, competent medicine agencies globally authorize below treatments (click for details):

NSAID associated benign gastric and duodenal ulcers

Population group: only adults (18 years old or older)

Treatment of NSAID associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Reflux oesophagitis

Population group: only adults (18 years old or older)

Reflux esophagitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of reflux oesophagitis

Population group: only adults (18 years old or older)

Preventive procedure and additionally Reflux esophagitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of NSAID associated benign gastric and duodenal ulcers

Population group: only adults (18 years old or older)

Prophylaxis of NSAID associated gastric and duodenal ulcers in patients at risk (such as age >65 or history of gastric or duodenal ulcer) requiring prolonged NSAID treatment.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Symptomatic gastro-oesophageal reflux disease

Population group: only adults (18 years old or older)

Gastroesophageal reflux disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: LANSOPRAZOLE Gastro-resistant capsules
Structured Product Labeling (SPL/PLR) 2020: PREVACID Delayed-release capsule / Delayed-release tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈